Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Ankit Kumar Singh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Sulfonamides, Antineoplastic Agents, Drug Design. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Science and Engineering Research Board, Indian Council of Medical Research, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
BRAF is one of the most commonly mutated oncogenes in human cancers. More than 90% of BRAF mutations are associated with malignant melanoma. Given the pivotal role of BRAF V600E/WT mutations in melanoma progression and therapy resistance, our study focused on the design of phenyl‐substituted pyrimidin‐benzenesulfonamide hybrids in the [αC‐OUT/DFG‐IN] conformation, inspired by previously synthesized molecules structurally related to FDA‐approved BRAF inhibitors. A total of ten derivatives were synthesized, and their ADME‐T properties, in silico binding affinities, in vitro cytotoxic activities against a melanoma cell line and BRAF V600E/WT kinase assay were thoroughly evaluated. All compounds exhibit selective and stronger affinity for the BRAF V600E mutant over the wild‐type BRAF protein and also adhere to Lipinski's Rule of Five. Overall, both computational and biological evaluations support that the synthesized compounds, particularly VA03 , exhibit greater potency and selectivity toward the BRAF V600E mutant protein. Furthermore, the presence of electron‐withdrawing groups at the R 1 position appears to significantly enhance the cytotoxic activity of these derivatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, India.
- Bioorganic and Medicinal Chemistry Research Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Prayagraj, Uttar Pradesh, India.
- Department of Pharmaceutical Analysis, Quality Assurance and Pharmaceutical Chemistry, School of Pharmacy, GITAM (Deemed to Be University), Hyderabad, Telangana, India.
- Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah, Saudi Arabia.
ORCID-Profile: Amita Verma
Förderung
- Science and Engineering Research Board
- Indian Council of Medical Research
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Singh, A. K., Prajapati, V., Sah, V. K., Kumar, A., Kalsi, A. S., Pathak, P., Khalilullah, H., Verma, A., & Kumar, P. (2025). Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70179
Vancouver
Singh AK, Prajapati V, Sah VK, Kumar A, Kalsi AS, Pathak P, et al. Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70179
BibTeX
@article{Singh2025,
author = {Singh, Ankit Kumar and Prajapati, Vineet and Sah, Vimlendu Kumar and Kumar, Adarsh and Kalsi, Amandeep Singh and Pathak, Prateek and Khalilullah, Habibullah and Verma, Amita and Kumar, Pradeep},
title = {Design, Synthesis, Molecular Docking, ADME ‐T and In Vitro Anticancer Assessment of Phenyl‐Substituted‐Pyrimidin‐Benzenesulfonamide Derivatives as Potential BRAF V600E / WT Inhibitors},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70179}
}
EUVIMED